Recipharm wins 3-year Parkinson’s drug contract

By Fiona BARRY

- Last updated on GMT

Recipharm previously manufactured Lecigon for clinical trial batches
Recipharm previously manufactured Lecigon for clinical trial batches

Related tags Pharmacology

CDMO Recipharm has signed a deal to manufacture a Parkinson’s therapy for Swedish pharma company LobSor.

LobSor Pharmaceuticals, based in Uppsala, is developing Lecigon, a treatment for advanced Parkinson’s disease currently at clinical stage.

Swedish contract development and manufacturing organisation (CDMO) Recipharm will manufacture the drug in its first three years on the market, and will help pay for development costs before then “against a mark-up on manufacturing prices, up to a certain volume, when Lecigon is produced for commercial sales.​”

The three-year agreement follows a previous deal whereby Recipharm manufactured the Parkinson’s candidate for a recent clinical trial.  

‘Costly and cumbersome’

Carl-Johan Spak, executive vice president of development and technology, Recipharm, said “We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of Lecigon, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease.​”

Roger Bolsöy, MD of LobSor Pharmaceuticals added “It is well known that pharmaceutical development is costly and can be cumbersome for a small company.

Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the Lecigon project.

“I am impressed that such a large organization as Recipharm has been able to show such entrepreneurial spirit and flexibility to facilitate the development of a company from the early stages through to commercialization.​”

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars